Displaying drugs 7726 - 7750 of 8495 in total
Selodenoson
Selodenoson is under investigation in clinical trial NCT00040001 (Safety and Efficacy Study of an A1-adenosine Receptor Agonist to Slow Heart Rate in Atrial Fibrillation).
Investigational
Matched Description: … Selodenoson is under investigation in clinical trial NCT00040001 (Safety and Efficacy Study of an A1- …
Vibecotamab
Vibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure).
Investigational
Matched Description: … Vibecotamab is under investigation in clinical trial NCT05285813 (A Phase II Study of Vibecotamab (Xmab14045 …
Dalosirvat
Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia).
Investigational
Matched Description: … Dalosirvat is under investigation in clinical trial NCT03742518 (A Study Evaluating the Efficacy and Safety of …
Suplatast
Suplatast is under investigation in clinical trial NCT05983471 (Efficacy and Safety of ME-015 (Suplatast Tosilate) in Cough Related to Idiopathic Pulmonary Fibrosis (COSMIC-IPF)).
Investigational
Matched Description: … Suplatast is under investigation in clinical trial NCT05983471 (Efficacy and Safety of ME-015 (Suplatast …
Ginsenoside Rg3
Ginsenoside Rg3 is under investigation in clinical trial NCT01757366 (Safety and Efficacy of Ginsenoside Rg3 in Combination With First-line Chemotherapy in Advanced Gastric Cancer).
Investigational
Matched Description: … Ginsenoside Rg3 is under investigation in clinical trial NCT01757366 (Safety and Efficacy of Ginsenoside …
KT-A261
KT-A261 is an adeno-associated viral vector serotype 2 (AAV2) encoded to express adalimumab. It is being investigated for the treatment of noninfectious uveitis.
Investigational
Matched Description: … It is being investigated for the treatment of noninfectious uveitis. …
Cerulenin
Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of fatty acids and sterols. In fatty acid synthesis, reported to bind in equimolar ratio to b-keto-acyl-ACP synthase. In sterol synthesis, inhibits HMG-CoA synthetase activity. It is also shown to inhibit feeding and induce...
Experimental
Matched Description: … Cerulenin is an antifungal agent whose activity interferes with or otherwise acts to prevent the formation of …
CYT006-AngQb
CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure. It is a unique treatment modality that...
Investigational
Matched Description: … CYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. ... It is a unique treatment modality that aims to address the issue of patient compliance by offering convenient …
Lumiliximab
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for...
Investigational
Matched Description: … antibody, for the potential treatment of allergic conditions. ... It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE …
Muraglitazar
Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients with type 2 diabetes. It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both alpha and gamma subtypes. In addition to improvements in blood glucose and hemoglobin A1c (HbA1c), muraglitazar treatment...
Investigational
Matched Description: … Muraglitazar (Bristol-Myers Squibb/Merck) is a new agent under investigation for the treatment of patients ... It belongs to a novel class of drugs that target the peroxisome proliferator-activated receptors, both …
Allogeneic Cardiosphere-Derived Cells
Cardiosphere-derived cells (CDCs) are derived from human neonatal heart tissue with a distinct antigenic profile (CD105+, CD45-, and CD90low). They exert their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of cell-cell communication. CDCs target multiple cytokine pathways associated with poor outcomes (e.g. TNFa, IFN-y, IL-1B, and...
Investigational
Matched Description: … their effects by secreting exosomes: nanometer-sized, membrane-bound vesicles used for the purpose of ... The anti-inflammatory effects of CDC work through polarizing macrophages and restoring tissue function …
Stem-cell derived exosome vesicle products
Mesenchymal stem cells (MSCs) exert their therapeutic effects through multiple modalities, including paracrine factors such as exosomes. Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication. Once secreted into extracellular fluid, exosomes are taken up by their target cells or carried to distant target sites. Various bioactive...
Investigational
Matched Description: … Exosomes are nanometer-sized, membrane-bound vesicles secreted for the purpose of cell-cell communication ... While many contain a conserved set of proteins, they also carry unique tissue type-specific proteins. ... These exosomes can also consist of VEGF and matrix metalloproteinase-9 (MMP-9) which aid in angiogenesis …
5-methyltetrahydrofolic acid
5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. It is generated by methylenetetrahydrofolate reductase from 5,10-methylenetetrahydrofolate and used to recycle homocysteine back to methionine by 5-methyltetrahydrofolate-homocysteine methyltransferases (also called methionine synthases).
Investigational
Nutraceutical
Matched Description: … 5-methyltetrahydrofolic acid is a methylated derivate of tetrahydrofolate. …
HGS-TR2J
HGS-TR2J is a novel agonistic human monoclonal antibody to TRAIL Receptor 2, in patients with advanced solid malignancies. It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial.
Investigational
Matched Description: … It is developed by Human Genome Sciences, Inc and is under Phase I of clinical trial. …
Poloxalene
Ethylene oxide/propylene oxide copolymer is used as a food additive. It belongs to the family of Epoxides. These are compounds containing a cyclic ether with three ring atoms (one oxygen and two carbon atoms).
Investigational
Vet approved
Matched Description: … It belongs to the family of Epoxides. …
Sulfaquinoxaline
Sulfaquinoxaline is a veterinary medicine which can be given to cattle and sheep to treat coccidiosis.It is available in Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as potential treatment of coccidiosis.
Vet approved
Matched Description: … Pakistan with Sanna Laboratories in combination with Amprolium and Vitamin K as potential treatment of …
Dasotraline
Dasotraline is a serotonin, norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of Binge Eating Disorder, Adult Attention Hyperactivity Disorder, Attention Deficit Hyperactivity Disorder, and Adult Attention Deficit Hyperactivity Disorder.
Investigational
Matched Description: … norepinephrine and dopamine reuptake inhibitor (SNDRI) that is under investigation for the treatment of …
RGX-111
RGX-111 is an adeno-associated virus vector AAV9 designed to deliver the α-L-iduronidase (IDUA) gene. Developed by REGENXBIO Inc., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).
Investigational
Matched Description: … ., it was investigated for the treatment of mucopolysaccharidosis Type I (MPS I).[L46666] …
Nemtabrutinib
Nemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)).
Investigational
Matched Description: … Nemtabrutinib is under investigation in clinical trial NCT05624554 (A Study of Nemtabrutinib vs Chemoimmunotherapy …
Plamotamab
Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)).
Investigational
Matched Description: … Plamotamab is under investigation in clinical trial NCT05328102 (Phase 2 Study of Plamotamab Combined …
MEDI3506
Tozorakimab (MEDI3506), developed by AstraZeneca, was investigated in multiple clinical trials to evaluate its safety, tolerability, efficacy, and pharmacokinetics across various conditions. These trials include NCT03096795 (completed; healthy participants, COPD patients, and healthy Japanese participants), NCT05070312 (completed; healthy Chinese participants), NCT04212169 (completed with results; atopic dermatitis), NCT04631016 (completed; COPD and...
Investigational
Matched Description: … exacerbations), and NCT06040086 (recruiting; symptomatic COPD with a history of exacerbations). ... requiring supplemental oxygen), NCT05742802 (recruiting; long-term study in COPD patients with a history of …
Iratumumab
Immunoglobulin G1, anti-(human CD30 (antigen)) (human monoclonal MDX-060 heavy chain), disulfide with human monoclonal MDX-060 light chain, dimer. Molecular weight is approximately 170,000 daltons. In phase I/II clinical trials for treatment of CD30+ lymphomas.
Investigational
Matched Description: … In phase I/II clinical trials for treatment of CD30+ lymphomas. …
Ulimorelin
Ulimorelin is a novel small molecule ghrelin agonist being developed by Tranzyme Pharma as a first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of the GI tract is severely impaired.
Investigational
Matched Description: … first-in-class treatment for both POI and diabetic gastroparesis, serious medical conditions in which motility of …
FT-1101
FT-1101 is a novel Bromodomain and Extra-Terminal motif (BET) inhibitor. FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor FT-1101 in Patients With Relapsed or Refractory Hematologic Malignancies).
Investigational
Matched Description: … [A257301] FT-1101 is under investigation in clinical trial NCT02543879 (Study of a Novel BET Inhibitor …
Freneslerbart
Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of Anti-fel D 1 Antibodies Injections in Cat-allergic Adolescent and Adult Patients With Allergic Rhinitis Who Live With a Cat).
Investigational
Matched Description: … Freneslerbart is under investigation in clinical trial NCT04981717 (A Study to Examine the Efficacy and Safety of …
Displaying drugs 7726 - 7750 of 8495 in total